Cardiol Therapeutics (CRDL) Competitors $1.10 -0.05 (-4.35%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRDL vs. CMPS, TKNO, ALLO, TRDA, ARCT, TSHA, HRTX, ATYR, ATAI, and PVLAShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include COMPASS Pathways (CMPS), Alpha Teknova (TKNO), Allogene Therapeutics (ALLO), Entrada Therapeutics (TRDA), Arcturus Therapeutics (ARCT), Taysha Gene Therapies (TSHA), Heron Therapeutics (HRTX), Atyr PHARMA (ATYR), Atai Life Sciences (ATAI), and Palvella Therapeutics (PVLA). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. COMPASS Pathways Alpha Teknova Allogene Therapeutics Entrada Therapeutics Arcturus Therapeutics Taysha Gene Therapies Heron Therapeutics Atyr PHARMA Atai Life Sciences Palvella Therapeutics Cardiol Therapeutics (NASDAQ:CRDL) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations, institutional ownership and community ranking. Do institutionals & insiders hold more shares of CRDL or CMPS? 12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 4.3% of COMPASS Pathways shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate CRDL or CMPS? Cardiol Therapeutics currently has a consensus target price of $8.40, indicating a potential upside of 663.64%. COMPASS Pathways has a consensus target price of $20.20, indicating a potential upside of 407.54%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Cardiol Therapeutics is more favorable than COMPASS Pathways.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CRDL or CMPS more profitable? COMPASS Pathways' return on equity of -63.85% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cardiol TherapeuticsN/A -194.40% -129.07% COMPASS Pathways N/A -63.85%-51.97% Does the media refer more to CRDL or CMPS? In the previous week, COMPASS Pathways had 7 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 8 mentions for COMPASS Pathways and 1 mentions for Cardiol Therapeutics. COMPASS Pathways' average media sentiment score of 1.31 beat Cardiol Therapeutics' score of 1.17 indicating that COMPASS Pathways is being referred to more favorably in the news media. Company Overall Sentiment Cardiol Therapeutics Positive COMPASS Pathways Positive Which has stronger valuation and earnings, CRDL or CMPS? Cardiol Therapeutics is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiol TherapeuticsN/AN/A-$20.84M-$0.37-2.97COMPASS PathwaysN/AN/A-$118.46M-$2.30-1.73 Does the MarketBeat Community favor CRDL or CMPS? COMPASS Pathways received 37 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 81.48% of users gave COMPASS Pathways an outperform vote while only 67.44% of users gave Cardiol Therapeutics an outperform vote. CompanyUnderperformOutperformCardiol TherapeuticsOutperform Votes2967.44% Underperform Votes1432.56% COMPASS PathwaysOutperform Votes6681.48% Underperform Votes1518.52% Which has more volatility and risk, CRDL or CMPS? Cardiol Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, COMPASS Pathways has a beta of 2.34, indicating that its share price is 134% more volatile than the S&P 500. SummaryCOMPASS Pathways beats Cardiol Therapeutics on 10 of the 16 factors compared between the two stocks. Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$95M$3.00B$5.56B$7.83BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-2.8230.4222.4818.48Price / SalesN/A498.92395.10103.59Price / CashN/A168.6838.1834.62Price / Book3.443.206.774.25Net Income-$20.84M-$72.35M$3.22B$248.23M7 Day Performance2.80%1.46%1.50%0.89%1 Month Performance18.59%8.79%4.01%3.53%1 Year Performance-46.60%-22.36%16.16%5.08% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol Therapeutics2.0249 of 5 stars$1.10-4.3%$8.40+663.6%-45.3%$95MN/A-2.8220Positive NewsCMPSCOMPASS Pathways2.4066 of 5 stars$3.38+8.0%$20.20+497.6%-53.6%$313.24MN/A-1.54120Upcoming EarningsNews CoveragePositive NewsTKNOAlpha Teknova1.9104 of 5 stars$5.78+0.3%$8.50+47.1%+274.7%$308.87M$37.75M-7.81240News CoverageALLOAllogene Therapeutics3.2171 of 5 stars$1.42-2.1%$9.29+554.1%-39.1%$308.52M$22,000.00-0.91310Positive NewsTRDAEntrada Therapeutics2.8762 of 5 stars$7.95-2.2%$25.67+222.9%-23.0%$298.88M$210.78M5.00110Upcoming EarningsNews CoverageHigh Trading VolumeARCTArcturus Therapeutics2.9829 of 5 stars$11.00+4.5%$59.20+438.2%-49.9%$298.32M$138.39M-4.95180News CoveragePositive NewsGap DownTSHATaysha Gene Therapies2.1385 of 5 stars$1.45+16.9%$6.63+356.9%-20.2%$297.33M$8.33M2.30180Analyst ForecastNews CoverageGap DownHRTXHeron Therapeutics3.7183 of 5 stars$1.93+4.9%$5.67+193.6%+4.3%$294.00M$144.29M-10.72300Upcoming EarningsNews CoveragePositive NewsGap UpATYRAtyr PHARMA2.3959 of 5 stars$3.28+5.8%$18.60+467.1%N/A$291.46M$235,000.00-3.4953Short Interest ↑News CoverageATAIAtai Life Sciences2.6737 of 5 stars$1.42-3.4%$10.50+639.4%-24.2%$283.69M$308,000.00-1.7580Positive NewsPVLAPalvella Therapeutics3.4225 of 5 stars$25.45+4.5%$44.43+74.6%N/A$280.43M$42.81M-2.10N/AAnalyst ForecastHigh Trading Volume Related Companies and Tools Related Companies CMPS Alternatives TKNO Alternatives ALLO Alternatives TRDA Alternatives ARCT Alternatives TSHA Alternatives HRTX Alternatives ATYR Alternatives ATAI Alternatives PVLA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRDL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRDL Stock Free CRDL Stock Alerts